Apollomics (NASDAQ:APLM) Downgraded by Wall Street Zen to “Sell”

Apollomics (NASDAQ:APLM) was downgraded by investment analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Sunday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Apollomics in a report on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Apollomics has a consensus rating of “Sell”.

Apollomics Stock Up 11.2%

Shares of APLM stock opened at $20.00 on Friday. Apollomics has a 52-week low of $3.66 and a 52-week high of $42.12. The company has a 50-day simple moving average of $17.57 and a two-hundred day simple moving average of $12.31.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.